ACRS · Aclaris Therapeutics, Inc.
AI read · Bad for ACRS
The AI's read
This weakens the case for bosakitug as a treatment because the trial did not meet its measured goals. Biomarker changes and good tolerability are encouraging, but they did not show that patients improved. Aclaris has other drug trials planned, but their results are still ahead.